What this study is
This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared to usual care.
What's being tested
- PATH
Intervention · BEHAVIORAL
PATH, a phone-delivered positive psychology intervention for patients who have undergone HSCT, consists of three 3-week modules. The first module focuses on gratitude and physical activity goal setting. The second module focuses on personal strengths and resources to enhance daily physical activity. The third module focuses on meaning and assessing barriers to physical activity. The third week of each module is an integration exercise dedicated to help participants explore practical ways of incorporating the themes for the given module into daily life. A trained interventionist will guide participants to complete each 30-minute weekly session.
Study details
- Sponsor
- Brigham and Women's Hospital
- Conditions
- Hematopoietic Stem Cell Transplant
- Enrolling
- 400 people
- Starts
- 2024-12-17
- Est. completion
- 2030-05-31
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Adult patients (aged 18 years and older) undergoing allogeneic HSCT and are approaching 100-days post-HSCT
- Ability to speak, read, and respond to questions in English or Spanish to complete study procedures
- Access to a basic telephone
You can't join if
- Patients who underwent allogeneic HSCT for benign hematologic conditions
- Patients with severe psychiatric or cognitive conditions, such as dementia, determined by their transplant oncologist to make them unable to provide informed consent or comply with study procedures
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (3)
3 open- Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Hermioni Amonoo, MD, MPP, MPH · Contact617-525-7472Hermioni_Amonoo@dfci.harvard.edu
- Hermioni Amonoo, MD, MPP, MPH · Principal investigator
RecruitingDuke Cancer Institute
Durham, North Carolina, United States
- Thomas LeBlanc, MD · Contactthomas.leblanc@duke.edu
Recruiting
Study team
Sponsor
Brigham and Women's Hospital
Study ID 23-691
Principal investigator
Hermioni Amonoo, MD, MPP, MPH
Brigham and Women's Hospital
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.